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Circular dichroismAngiotensin II (AII) is the active octapeptide product of the renin enzymatic cascade, which is responsible for
sustaining blood pressure. In an attempt to establish the AII-receptor-bound conformation of this octapeptide,
we designed conformationally constrained analogues by scanning the entire AII sequence with an i-(i+2)
and i-(i+3) lactam bridge consisting of an Asp-(Xaa)n-Lys scaffold. Most analogues presented low agonistic
activity when compared to AII in the different bioassays tested. The exceptions are cyclo(0-1a) [Asp0, endo-
(Lys1a)]-AII (1) and [Asp0, endo-(Lys1a)]-AII (2), both of which showed activity similar to AII. Based on
peptide 1 and the analogue cyclo(3–5)[Sar1, Asp3, Lys5]-AII characterized byMatsoukas et al., we analyzed the
agonistic and antagonistic activities, respectively, through a new monocyclic peptide series synthesized by
using the following combinations of residues as bridgehead elements for the lactam bond formation: D- or L-
Asp combined with D- or L-Lys or L-Glu combined with L-Orn. Six analogues showed an approximately 20%
increase in biological activity when compared with peptide (1) and were equipotent to AII. In contrast, six
analogues presented antagonistic activity. These results suggest that the position of the lactam bridge is more
important than the bridge length or chirality for recognition of and binding to the angiotensin II AT1-receptor.nitrile; AII, angiotensin II; BOP,
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Angiotensin II (AII) is a natural peptide produced in the blood as a
result of two different enzymatic hydrolyses that takes place in the
renal hypertension system [1]. Kidney juxtaglomerular cells [2], in
certain circumstances, liberate an enzyme called renin that acts on thefull protein substrate angiotensinogen to liberate the angiotensin I
peptide [3]. This decapeptide is hydrolyzed by the angiotensin-
converting enzyme to generate the peptide AII [4,5]. The renin–
angiotensin system plays an important role in the regulation of blood
pressure. AII, the hormone responsible for this physiological function,
interacts with several tissues, including the adrenal cortex, myocar-
dial tissue, vascular ﬂat muscle [6], the kidneys and the brain. The
effects of AII include modulating the liberation of aldosterone from
the adrenal cortex adrenal [7], the heart rate control [8], vascular
tonus [9], glomerular ﬁltration and the pituitary secretion of the
vasopressin [10,11]. AII also acts in the outlying central nervous
system of mice [12]. These functions of AII can be altered in vascular
diseases such as hypertension and arteriosclerosis, promoting the
growth and hypertrophy of the ﬂat and heart muscles [13]. An
understanding of the AII-receptor interaction with the AII peptide is
crucial for the control of the renin–angiotensin system; however, the
greatest difﬁculty in achieving this goal is establishing the bioactive
conformation of AII. Over many decades, the conformation of AII has
been studied using different approaches, such as CD studies [14],
Raman spectroscopy [15] and NMR [16–18]. Structure-activity
relationship studies focusing on AII have demonstrated the impor-
tance of the amino acid residues Tyr4, His6 and Phe8 for biological
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receptor desensitization rates, can be obtained with an amino acid
replacement. This antagonistic behavior is highly dependent on the
nature of the amino acid in position 8 [21] and by aliphatic amino
acids this peptide (Ile, Ala and Thr). AII competitive antagonists are
also obtained by modifying the hydroxyl group of the Tyr4 residue
[22].
In an attempt to characterize the bioactive conformation of this
hormone, several cyclic analogues have been created by the incorpo-
ration of disulﬁde or lactambridges and tested for their activity [23–25].
Among them, the following bridged monocyclic disulﬁdes demonstrat-
ed high afﬁnity for the AT1 receptor: c[Cys3,5]-AII, c[Cys3, Hcy5]-AII, c
[Hcy3, Cys5]-AII and c[Hcy3,5]-AII [23,26–31]. In addition, cyclic
analogues were created by inserting a lactam bridge in the same region
of the molecule, which generated relevant antagonistic activity [27].
In this work, we performed a systematic AII structure–activity
relationship study using conformationally restricted analogues created
via the incorporation of a lactam bridge. Peptides were designed by
scanning the entire AII sequence with i-(i+2) and i-(i+3) lactam
bridges, consisting of an Asp-(Xaa)n-Lys scaffold. All the amino acids
residues important for the biological activity of AII (i.e., His, Phe side
chains, the hydroxyl group of Tyr, and the C-terminal carboxylic group)
were left unchanged. The effect of lactamization was also evaluated by
testing the corresponding linear analogues. The agonistic and antago-
nistic effects of the peptides were compared to AII using Chinese
hamster ovary (CHO) cells transfected with the AT1-receptor and then
grown in suspension on a Cytosensor microphysiometer. Furthermore,
the contractile responses of isolated guinea-pig ileum and rat-uterus
preparations as well as the arterial pressure alterations induced by the
peptides were also evaluated. The conformational behaviors of the
compounds were analyzed using circular dichroism (CD).
2. Experimental procedures
2.1. Peptide synthesis, puriﬁcation and characterization
AII and its analogues were synthesized using a common protocol
for manual solid-phase methodology and the tert-butoxycarbonyl
(t-Boc) strategy [32,33]. Chloromethylated resin [34] with a degree of
substitution varying from 0.5 to 0.8 mmol/g was employed. The
Nα-terminal protecting group was removed with 50% triﬂuoroacetic
acid (TFA) in dichloromethane (DCM) in the presence of 2%
anisole for 20 min. Couplings were carried-out using a 2.5-fold
excess of 1,3-diisopropylcarbodiimide/N-hydroxybenzotriazole
(DIC/HOBt) in DCM-dimethylformamide (DMF) (1:1, v/v) and were
monitored using the Kaiser ninhydrin test [35]. Recouplings for 1 h
were performed when needed using a 2.5-fold excess of 2-(1H-
benzotriazole-1-yl)-1,1,3,3-tetramethyluronium tetraﬂuoroborate
(TBTU) in the presence of N,N-diisopropylethylamine (DIPEA) in
DCM/N-methylpyrrolidone (NMP) (1:1, v/v) [36]. Acetylations were
performed using 50% acetic anhydride in DMF for 15 min, when
required. Orthogonal protection of the aspartic acid side chain
residues with OFm (Fluorenylmethyloxycarbonyl ester) and the
lysine residues with Fmoc (9-ﬂuorenylmethyloxycarbonyl) were
employed. Side-chain to side-chain cyclization (lactamization) was
performed with the peptide still attached to the resin [37]. After
washes with DCM and DMF, the OFm and Fmoc groups were
removed by treating the peptide with 20% piperidine in DMF [38,39].
The lactamization reaction was performed using a 3.0-fold excess
of (benzotriazol-1-yloxy)tris(dimethylamino)phosphonium hexa-
ﬂuorophosphate (BOP) to the peptide concentration in the presence
of excess DIPEA in 20% dimethyl sulfoxide (DMSO) dissolved in NMP
[37] and the reaction progress was monitored using the Kaiser
ninhydrin test. Dry-protected peptidyl-resin was exposed to anhy-
drous HF in the presence of 5% anisole and 5% dimethyl sulﬁde (DMS)
for 75 min at 0 °C. Excess HF and scavengers were eliminated underhigh vacuum. The crude peptides were precipitated with anhydrous
diethyl ether, separated from ether-soluble reaction components by
ﬁltration, extracted from the resin with 5% acetic acid in water and
lyophilized. Crude lyophilized peptides were then puriﬁed by
preparative reverse-phase high-performance liquid chromatography
(RP-HPLC) in two steps: triethylammonium phosphate (TEAP) at pH
2.25 and 0.1% TFA on a Waters Associates system (Model Prep 4000).
Brieﬂy, the peptides were loaded onto a Vydac C18 (25 mm×250 mm,
15 μm particle size, 300 Å pore size) column at a ﬂow rate of
10.0 mL/min and eluted using linear gradients (slope 0.33% B/min) of
TEAP (pH=2.25)/Acetonitrile (ACN) with detection at 220 nm.
Selected fractions were collected and converted to the TFA salt by
loading on a preparative column as described above and eluting with a
linear gradient (slope 0.33% B/min) of solvents A (0.1% TFA in water)
and solvent B (75% ACN in solvent A), at a ﬂow rate of 10.0 mL/min.
Selected fractions containing the puriﬁed peptide were pooled and
lyophilized.
Puriﬁed peptides were characterized by liquid-chromatography
electrospray-ionization mass spectrometry (LC/ESI-MS), capillary
electrophoresis (CE) (Tables S1 and S2 in the Supplementary
material), and amino acid analysis (AAA; data not shown).
LC/ESI-MS data were obtained on a Micromass instrument, model
ZMD, coupled to a Waters Alliance system (model 2690) and
photodiode array detector (model 996), using a Phenomenex Gemini
C18 column (2.0 mm×150 mm, 3.0 μm particle size, 110 Å pore size).
Solvent Awas 0.1% TFA inwater, and solvent Bwas 60% ACN in solvent
A. The gradient was 5–95% B for 30 min with a λrange of 190–300 nm.
Mass measurements were performed in a positive mode with the
following conditions: mass range between 500 and 2000 m/z;
nitrogen gas ﬂow of 4.1 L/h; capillary, 2.3 kV; cone voltage of 32 V;
extractor, 8 V; source heater, 100 °C; solvent heater, 400 °C; ion
energy, 1.0 V; and a multiplier of 800 V.
Capillary electrophoresis proﬁles were obtained using a Waters
System,model CIA (Capillary Ion Analyzer), by hydrostatic injection in
25 s, utilizing phosphate buffer at pH 2.50, λ=214 nm, a silica
capillary (75 μm×60 cm), voltage of 20 kV at a temperature of 30 °C.
Amino acid analysis of the peptides previously hydrolyzed in 6 M
HCl at 110 °C for 72 h were performed by ion-exchange chromatog-
raphy in a Biochrom 20 Plus amino acid analyzer, using the three-
buffer system under standard conditions recommended by the
manufacturer. The molar ratios of the amino acids were established
by considering the concentration unitary of the closest amino acid of
the average for all the residues.
2.2. Circular dichroism studies
Far-UV (190–250 nm) CD spectra were recorded at 20 °C using a
1 mm path length quartz cell in a Jasco J180 spectropolarimeter. All
spectra were recorded after an accumulation of four runs. The scan rate
was 50 nm/min for all measurements with bandwidths of 0.5 nm. All
peptidesweremeasured in the following four solutions:water (pH=7.4),
20 mM sodium dodecyl sulfate (SDS), 50% 2,2,2-triﬂuoroethanol (TFE) in
water, and 60% methanol (MeOH) in water. The CD spectra for the SDS,
TFE and MeOH solutions were subtracted, and a Fourier transform ﬁlter
(FFT) was applied to minimize background effects.
2.3. Cell culture and cell transfection
Chinese hamster ovary (CHO) cells were maintained in Dulbecco's
modiﬁed Eagle's medium from GIBCO-BRL. DMEMwas supplemented
with 10% fetal calf serum and 100 UI/mL of gentamycin and
maintained at 37 °C in a humidiﬁed 5% CO2 atmosphere. An
expression plasmid containing the wild-type rat AT1 receptor was
permanently transfected into CHO cells using the Lipofectin reagent
(Life Technologies), as described by the manufacturer. Cells
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G418 (500 mg/mL) in DMEM.
2.4. Extracellular acidiﬁcation rate measurements
The use of a Cytosensor microphysiometer is a powerful technique
to evaluate the responsiveness of different cell lines to a variety of
bioactive ligands by measuring small changes in the concentration of
H+ ions in the sensor chamber [40]. This method has been used
extensively to measure the effects of signal transduction after the
application of cell surface receptor ligands, both agonists and
analogues, for many families of G protein-coupled receptors [41–
43]. Cells expressing the AT1 receptor were plated in DMEM onto
membrane polycarbonate capsule cups at a density of 5×105 cells/
cup, approximately 18–24 h prior to the experiment. The capsule cup
insert assemblywas then placed into the pH-sensitive sensor chamber
of the Cytosensor system (Molecular Devices Corporation) [41].
DMEM not supplemented with fetal calf serum was pumped through
the chambers, bathing the cells at a rate of 100 μL/min. This running
mediumwas devoid of sodium bicarbonate and had a 1 mM buffering
capacity supplied by phosphate. Physiological osmolarity was
obtained by the addition of NaCl. The assembled cup was then
transferred to sensor chambers containing 1 mL of low buffered
(1 mM sodium phosphate) DMEM containing 0.1% bovine serum
albumin (BSA). This DMEM was without bicarbonate but contained
2 mM glutamine and an additional 44.4 mM NaCl as replacement for
the bicarbonate and to adjust the osmolarity. The sensor chambers
were placed on the Cytosensor and allowed to equilibrate for 30–
40 min before the beginning of the experiment. Mediumwas pumped
through the chambers at a rate of 100 μL/min, and the pump cycle was
90 s on followed by 20 s off at 37 °C. To assess shifts in the
extracellular acidiﬁcation rate, cells were stimulated over a period
of 30 s, with chemical compounds at concentrations of 10−6 and
10−7 mol/L. All measurements were performed in quadruplicate, and
the data were analyzed by nonlinear regression analysis using PRISM
3.02 (Graph-Pad Software, San Diego, CA).
2.5. Bioassays
For isolated smooth muscle preparations, rats and guinea-pigs
were killed by a blow to the head and exsanguinated [44]. Their
organs were removed and mounted in an organ bath. All pharmaco-
logical experiments followed the current guidelines for the care and
use of laboratory animals as well as the ethical guidelines for
investigations, and these experiments were pre-approved by the
Animal Care Committee of the Federal University of São Paulo. All
bioassay experiments were carried out in triplicate and generated
equivalent results. The biological potencies were calculated in relation
to the AII sample, which was taken to be 100%.
2.5.1. Guinea-pig ileum
The lower portion of the ileumwas excised from guinea pigs (250–
350 g) and washed in warm Tyrode's solution with the following
composition: 136.8 mM NaCl; 2.7 mM KCl; 1.36 mM CaCl2; 0.49 mM
MgCl2; 0.36 mM NaH2PO4; 11.9 mM NaHCO3; and 5.5 mM glucose.
Segments that were 4.5 cm in length were cut and suspended in 5-mL
organ baths containing aerated Tyrode's solution bubbled with a gas
mixture of 95% O2/5% CO2; the temperature was maintained at 37 °C.
Preparations were mounted under a 1 g load and were connected to a
lever front entry to record the isotonic contractile response, using
with 6× magniﬁcation, in a kymograph (Palmer).
Peptideswere dissolved inwater (1.0 mg/mL), diluted in a 0.9%NaCl
solution and added to the perfusion chambers, staying in contact with
the organ for 90 s. After treatment, the preparation was washed and
allowed to settle for 3.5 min (with an interval between doses of
5.0 min).2.5.2. Rat-uterus preparations
Uterine horns from female Wister rats (200–250 g) that had
received 100 mg diethylstilbestrol per 100 g body weight 48 h before
the experiments were removed and mounted in 5-mL organ baths
containing De Jalon's solution of the following composition: 137 mM
NaCl; 5.36 mM KCl; 0.41 mM CaCl2; 0.19 mM MgCl2; 0.36 mM
Na2HPO4; 11.9 mM NaHCO3; and 5.5 mM glucose. The solution was
bubbled with a gas mixture of 95% O2/5% CO2, and the temperature
was maintained at 30 °C to inhibit the spontaneous contractions
observed at higher temperatures. Preparations were mounted under a
1.5 g load and were connected to a lever front entry to record the
isotonic contractile response, with 6× magniﬁcation, in a kymograph
(Palmer).
2.5.3. Blood pressure measurements
Experiments were performed using male Wistar rats (290–300 g,
n=3 for each group). One day before the experiment, the rats were
anesthetized (450 mg/kg chloral hydrate, ip — intraperitoneal), and a
polyethylene catheter (PE-10 connected to PE-50) was inserted into
the abdominal aorta, through the femoral artery, for blood pressure
measurements. For intravenous injections, a polyethylene cannula
was implanted into the femoral vein. The polyethylene cannula was
closed by metallic pins and ﬁlled with isotonic saline and was driven
subcutaneously to the interscapular region of the backs of the animals.
After injections with an isotonic peptide solution, changes in arterial
pressure were recorded using a transducer (Hewlett-Packard model
FTA-10) through an ampliﬁer (Hewlett-Packard model E805) and a
potentiometric recorder (ECB model RB102).
2.6. Statistical analyses
The Kruskal–Wallis test and Dunnett's multiple comparison test
(GraphPad InStat version 5.00 for Windows, GraphPad Software, San
Diego, California, USA, www.graphpad.com) were used to assess the
statistical signiﬁcance of the differences between the control and the
analogue-treated groups.
3. Results
3.1. Synthesis and characterization
Angiotensin II analogues were manually synthesized on a
chloromethylated resin using the solid phase method and a t-Boc
strategy. Main chain assembly was mediated by DIC, TBTU and BOP.
Orthogonal protection of the side chains of the bridge-head
components were employed to allow for cyclization with the peptide
still attached to the resin. The best cyclization performance was
obtained when lactamization was mediated by BOP in the presence of
excess DIEA. Peptides were cleaved and deprotected in anhydrous HF
and puriﬁed with RP-HPLC. All peptides were analyzed by CE, LC/ESI-
MS and AAA. Peptide characterization by AAA and mass spectroscopy
were in agreement with the expected theoretical values. Analysis by
RP-HPLC and CE showed that all compounds were greater than 96%
pure (Table S1 and Table S2 — Supplementary material).
3.2. Circular dichroism
Circular dichroism spectra for some peptides in water, in 20 mM
SDS, in 50% TFE or in 60% MeOH are shown in Fig. 1.
3.3. Biological assays
Bioassays using the Cytosensor microphysiometer measured the
speed of acidiﬁcation of the medium surrounding CHO cells
transfected with AT1 angiotensin II receptor. These assays showed
highly signiﬁcant agonistic activities for the analogues, in comparison
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lactam bridge screening of the AII molecule showed that of the 30
tested analogues, only four of them presented signiﬁcant agonistic
activities: cyclo(0-1a )[Asp0, endo-(Lys1a)]-AII (1), [Asp0, endo-
(Lys1a)]-AII (2), cyclo(1a-2a)[endo-(Asp1a), endo-(Lys2a)]-AII (3),
and [endo-(Asp1a), endo-(Lys2a)]-AII (4) (Table 1, Fig. 2 and Table S1).
The effect of lactamization was also evaluated and was shown to
be important, as the linear analogues (compounds 2 (55%) and 4
(29%), Fig. 2) are signiﬁcantly less potent than the corresponding
lactamized peptides (compounds 1 (87%) and 3 (53%), Fig. 2).
As cyclo(0-1a)[Asp0, endo-(Lys1a)]-AII (1) demonstrated the best
bioactivity, we used this compound as a lead compound in the design
of new AII analogues (compounds 5 to 10, Table 1). After further
synthesis, the effects of chirality (compounds 5 to 7) and the length
(compounds 8 to 10) of the bridgehead components on peptide
activity was evaluated. It is clear that the chirality and bridge length
are not critical for recognition by the AT1 receptor. The new analogues
demonstrate a 20% increase in biological activity.
To discover new antagonists, we designed an AII antagonist series
based on cyclo(3–5)[Sar1,Asp3,Lys5]-AII [2] (compounds 11 to 16,
Table 1). Antagonistic effects were measured at 10−6 M and 10−7 M
concentrations; the results are presented in Fig. 3.4. Discussion
Many efforts have been made to establish the conformation of
the AII molecule when it is attached to its receptor. Many
techniques have been employed in this pursuit, including molecular
modeling [45], pseudopeptide design [46] and the synthesis and
biological testing of conformationally constrained analogues, espe-
cially using side chain peptide cyclization, such as lactam or
disulﬁde bridges [29].
In this work, we continue to describe a systematic study of the
structure-activity relationship of AII analogues that contain lactam
bridges in their structures. The effects of structural restriction on the
recognition of peptides by the AII-receptor were studied in vivo and in
vitro. Moreover, a conformational study was performed using circular
dichroism in an attempt to correlate the biological activity with the
secondary structures of the AII analogues.
In the CD spectra for AII in water (Fig. 1A), we observed a negative
minimum below 200 nm. This minimum is primarily associated with
unfolded and/or random conformations, suggesting that this peptide
mainly adopts a random structure in water, as is expected for small
peptides in solution. The addition of SDS, TFE or MeOH induced some
folded secondary structure in the AII peptide.
Table 1
Biological activities of the peptides in isolated smooth muscle preparations and in the rat blood pressure.
No Compound namea Sequence Guinea pig ileum Rat uterus Rat blood pressure
0 Angiotensin II Asp-Arg-Val-Tyr-Ile-His-Pro-Phe 100 100 100
1 Cyclo(0-1a )[Asp0, endo-(Lys1a)]-AII Asp-Asp-Lys-Arg-Val-Tyr-Ile-His-Pro-Phe 51.0±2.2 14.8±0.8 10.5±1.0
2 [Asp0, endo-(Lys1a)]-AII Asp-Asp-Lys-Arg-Val-Tyr-Ile-His-Pro-Phe 25.2±1.7 10.1±0.9 10.6±0.5
3 Cyclo(1a-2a)[endo-(Asp1a), endo-(Lys2a)]-AII Asp-Asp-Arg-Lys-Val-Tyr-Ile-His-Pro-Phe 1.1±1.0 1.5±0.3 2.0±0.8
4 [endo-(Asp1a), endo-(Lys2a)]-AII Asp-Asp-Arg-Lys-Val-Tyr-Ile-His-Pro-Phe bNA b0.5 2.0±0.2
5 Cyclo(0-1a )[Asp(D)0 , endo-(Lys1a)]-AII DAsp-Asp-Lys-Arg-Val-Tyr-Ile-His-Pro-Phe 3.5±0.4 11.5±1.2 25.4±1.3
6 Cyclo(0-1a )[Asp0, endo-(Lys(D)1a )]-AII Asp-Asp-DLys-Arg-Val-Tyr-Ile-His-Pro-Phe 23.5±2.5 11.5±2.1 32.5±1.2
7 Cyclo(0-1a )[Asp(D)0 , endo-(Lys(D)1a )]-AII DAsp-Asp-DLys-Arg-Val-Tyr-Ile-His-Pro-Phe 19.5±0.9 16.5±1.1 25.5±1.9
8 Cyclo(0-1a )[Glu0, endo-(Lys1a)]-AII Glu-Asp-Lys-Arg-Val-Tyr-Ile-His-Pro-Phe 31.5±2.1 22.0±0.6 50.3±1.3
9 Cyclo(0-1a )[Asp0, endo-(Orn1a)]-AII Asp-Asp-Orn-Arg-Val-Tyr-Ile-His-Pro-Phe 22.4±1.3 18.2±0.4 20.0±2.1
10 Cyclo(0-1a )[Glu0, endo-(Orn1a)]-AII Glu-Asp-Orn-Arg-Val-Tyr-Ile-His-Pro-Phe 31.5±0.2 17.1±1.2 34.5±1.4
11 Cyclo(3a-4a)[Sar1, endo-(Asp3a), endo-(Lys4a)]-AII Sar-Arg-Val-Asp-Tyr-Lys-Ile-His-Pro-Phe b0.5 bNA b0.5
12 Cyclo(3a-4a)[Sar1, endo-(Asp3a), endo-(Orn4a)]-AII Sar-Arg-Val-Asp-Tyr-Orn-Ile-His-Pro-Phe b0.5 b0.5 b0.5
13 Cyclo(3a-4a)[Sar1, endo-(Glu3a), endo-(Lys4a)]-AII Sar-Arg-Val-Glu-Tyr-Lys-Ile-His-Pro-Phe bNA b0.5 5.0±2.3
14 Cyclo(3a-4a)[Sar1, endo-(Glu3a), endo-(Orn4a)]-AII Sar-Arg-Val-Glu-Tyr-Orn-Ile-His-Pro-Phe 1.0±0.8 b0.5 bNA
15 Cyclo(3-4a)[Sar1, (Asp3), endo-(Lys4a)]-AII Sar-Arg-Asp-Tyr-Lys-Ile-His-Pro-Phe bNA b0.5 bNA
16 Cyclo(3a-5)[Sar1, endo-(Asp3a), (Lys5)]-AII Sar-Arg-Val-Asp-Tyr-Lys-His-Pro-Phe b0.5 3.0±1.1 3.5±0.7
Peptide concentration was 10−6 M (n=3). The experimental conditions were detailed in the Experimental procedures.
a According to IUPAC-IUB, Biochemistry 1967, 6(1), 362–368.
b No activity detected (limit concentration=10−5 M).
5V.X. Oliveira Jr. et al. / Regulatory Peptides 172 (2011) 1–7This acquisition of regular structure is suggested by the appear-
ance of negative minima near 225 nm and by the appearance of
slightly positivemaxima near 200 nm, which are characteristic of beta
elements [47]. The structure induced with the addition of TFE is in
agreement with the recently proposed model by Spyroulias and
collaborators [48] for AII in the presence of 2,2,2 triﬂuoroethanol in
water. In this model, AII presents an S-shape backbone conformation
with the existence of beta-turn-like structures. Although the U-shape
has been proposed to be essential for the biological activity of this
peptide, the transformation of the S-shape conformation to a
functional U-shape conformation is an important point to consider.
Because this cooperative transformation decreases the possibility of
π–π* stacking geometry between tyrosine and histidine residues,
these two residues would be able to emerge from the stacking
structure, stimulating a response from the receptor [48].
The spectra of analogues 1 and 2, which are shown in Fig. 1B and C,
respectively, present a similar behavior. The negative minimum near
200 nm for the peptide inwater also suggests that these analogues adopt
a random conformation in water, similar to the native angiotensin II.
When SDS,MeOHor TFEwere added, the CD spectra of both analogues 1Fig. 2. Relative agonistic potency of angiotensin II analogues obtained bymeasurements
of the extracellular acidiﬁcation rate on a Cytosensor microphysiometer using CHO cells
transfected with wild-type rat AT1 receptor. The peptide concentration was 10−7 mol/L
(n=4). The data were statistically analyzed using a Dunnett's multiple comparison
test, which shows that the activities of analogues 2 through 4 are signiﬁcantly different
(pb0.0001) in comparison with the control (AII). In contrast, the activities of analogues
1 and 5 through 10 are not signiﬁcantly different (pN0.05) when compared to the
control.and 2 showed a negative minimum near 225 nm and a positive
maximum below 200 nm, suggesting the presence of beta structures.
This conformational change is more evident in analogue 1 than in
analogue 2 and could be correlated with the biological results
obtained for analogue 1, which demonstrated a potency similar to
AII (Fig. 2). These analogues are the only ones that allow placement of
the Arg2, Tyr4, Ile5 and His6 side chains to the same side, as proposed
by Tzakos [49]. Analyzing the results, we can suggest that the N-
terminal portion of the AII molecule is more susceptible to alterations
than the remainder of the molecule and that analogue 1 adopts a
structure similar to AII. The side chain-to-side chain bridging
cyclization, observed in analogue 2, produces a signiﬁcant effect on
the biological activity, which decreasedmore than 30% in all bioassays
evaluated, with exception of the measurements of rat blood pressure,
which are similar to the controls. Our results are in agreement with
other studies. Schreier et al. synthesized and tested AII analogues
containing the paramagnetic amino acid TOAC in several positions of
the AII molecule [50]. The authors obtained the equipotent analogue
(TOAC1-AII), which had replaced the amino acid residue Asp1 with
TOAC. In another work, Motta et al. [51] have shown that an N-Fig. 3. The antagonistic effects of angiotensin II analogues obtained by measuring the
extracellular acidiﬁcation rate, on a Cytosensor microphysiometer using CHO cells
transfected with wild-type rat AT1 receptor. The peptide concentrations were as
follows: A=10−6 mol/L and B=10−7 mol/L (n=4). The data were statistically
analyzed using a Dunnett's multiple comparison test, which shows that the activities
analogues 16A and 16B are signiﬁcantly different (pb0.0001) in comparison with the
control (AII). In contrast, the activities of the other analogues are not signiﬁcantly
different from the control (pN0.05).
6 V.X. Oliveira Jr. et al. / Regulatory Peptides 172 (2011) 1–7terminal modiﬁcation using Fmoc- or OFm-type groups coupled to the
Asp1 residue induced tachyphylaxis via an alternate mode of
molecular interaction between the N-terminal portion of AII and its
AT1 receptor.
In an attempt to evaluate the chirality and size of the lactam ring,
we exchanged the Asp and Lys residues of the analogue cyclo(0-1a)
[Asp0, endo-(Lys1a)]-AII (1) for D-Asp or L-Glu and for D-Lys or L-Orn
residues, respectively. In general, we observed a 20% increase in the
biological activity (in vitro), as comparedwith analogue 1 (Fig. 2), and
we obtained different results when studying the isolated smooth
muscle preparations and for the rat blood pressure measurements
(Table 1). Based on these results, we suggest that the size, chirality
and bridgehead elements of the lactam bridge are not so important for
recognition and binding to the AII AT1-receptor because these
exchanges should not affect the U-shaped structure of the Tyr4-Ile5-
His6-Pro7 sequence [49].
In water, the CD spectrum of analogue 8 presents a negative
minimum near 200 nm that is shifted to 225 nm when SDS, TFE or
MeOH is added. This minimum, together with the presence of a
positive maximum near 200 nm, indicates the presence of regular
structures, mainly beta elements. Moreover, all the peptides in the
same group as analogue 8 (peptides 5 to 10) presented equivalent
conformational changes (data not shown). It is interesting to note that
analogues 1 and 2 as well as 5 through 10 demonstrated biological
activity in all the bioassays tested and that their conformations can be
affected by SDS, TFE or MeOH in a similar way to that of the native
angiotensin II. These studies clearly indicate a similarity in the
conformational behavior of the analogues with that observed for the
native AII, which is shown by NMR to possess a bend that is stabilized
by interactions between residues 3 and 4 (Val and Tyr) [52]. In
contrast, CD studies of the inactive analogues (Table S2) show that the
addition of SDS, TFE or MeOH did not induce important changes in the
secondary structure of these compounds (e.g., [endo-(Asp6a) and
endo-(Lys7a)]-AII; Fig. 1E), which show similarity to the spectra
obtained in both water (with a minimum at 199 nm) and the other
solvents. In fact, the solvent medium caused a very small shift in the
negative minimum (from 199 nm to 203.5 nm or 205 nm), indicating
mainly unordered conformations and no considerable changes to the
secondary structure.
Our results show that an insertion of Lys and Asp residues in
another region of the AII molecule exerted a negative effect in the
biological assays (analogue 4), even producing inactive analogues
(Table S2). This fact is probably due to the side chain charge for these
residues (in the linear analogues) or changes in the distances between
the amino acids residues that are important in facilitating the
biological activity of AII (i.e., Asp1, Arg2, Tyr4, His6 and Phe8). These
factors induce conformational changes in the AII molecule that
impede recognition by and binding to the AII AT1-receptor, according
to Tzakos et al., who have suggested a fairly compact folded structure
for AII [49].
The antagonistic results obtained (see Fig. 3) show that analogues 11
to 15 do not inhibit the AII response at two different concentrations
(10−6 mol/L and 10−7 mol/L). In contrast, analogue 16 demonstrated
approximately 35% inhibition at both concentrations tested. When we
compare the primary sequence of analogues 16 and 11, we hypothesize
that the increased potency may be due to the absence of the isoleucine
residue. This isoleucine might induce or stabilize a backbone turn
conformationwhen thepeptide interactswith the receptor [53]. Thus, in
analogue 16, the lactam bridge probably mimicked the interaction
betweenArg2 and Ile5. These antagonist analogues donot showchanges
in their secondary conformations in the presence of SDS, TFE or MeOH.
CD spectra of analogue12 (Fig. 1F) inwater or in the presenceof SDS, TFE
or MeOH present a negative minimum near 225 nm. The spectra of the
peptide in water or in SDS show an unusual behavior, indicated by the
presence of a negative peak near 200 nm, as opposed to a positive
maximum. Nevertheless, the negative minima, which are characteristicof structures with high beta content, are present in the peptide spectra
taken in water. The overall shapes of the spectra remain unaltered upon
the addition of SDS, TFE orMeOH. All spectra for this group of analogues
presented this unusual shape, similar to Wilkes's antagonists [53], and
this can be attributed to the presence of a Sar residue, which can disturb
the beta structure. This kind of approach may offer the basis for the
development of new drugs to be used in the treatment of hypertension.
Supplementarymaterials related to this article can be found online
at doi:10.1016/j.regpep.2011.05.015.
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